You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: NCI

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. The nGoggle: A portable brain-based device for assessment of visual function deficits

    SBC: NGOGGLE INC            Topic: N

    PROJECT SUMMARY Assessment of loss of visual function outside the foveal area is an essential component of the management of numerous conditionsincluding glaucomaretinal and neurological disordersDespite the significant progress achieved with the development of standard automated perimetrySAPmany decades agoassessment of visual field loss with SAP still has significant drawbacksSAP testing is limi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY State of the art techniques result inyear solid organ graft loss ofto overin cardiopulmonary organ transplantationEstablishment of donor specific immunological toleranceDSITa condition in which a recipient accepts a transplant without immunosuppressionwhile retaining the ability to fight infectionswould reduce graft loss and transplant related complicationsThe only identified metho ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Hierarchical, Layout-Aware, Radiation Effects Tools Vertically Integrated into an EDA Design Flow for Rad-Hard by Design

    SBC: Reliable MicroSystems, LLC            Topic: DTRA16A003

    The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  6. Compact Laser Drivers for Photoconductive Semicond

    SBC: SCIENTIFIC APPLICATIONS & RESEARCH ASSOCIATES            Topic: DTRA16A004

    For effective protection against radiated threats, it is important to understand not only the physics of the threats, but also to quantify the effects they have on mission-critical electrical systems. Radiated vulnerability and susceptibility testing requires delivery of high peak power and peak electric fields to distant targets. The most practical solution to simulate such environments on large ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  7. Deriving Bone Density from Thoracic CT Scans, STTR Phase II

    SBC: BDI, Inc.            Topic: NIAMS

    ABSTRACT Osteoporosis is a major cause of disability and morbidity in our populationAs many asmillion Americans have osteoporosis andmillion more have osteopeniaHoweverbone mineral densityBMDassessment does not occur in many Americans when indicated and measure currently requires a separate referral and separate imaging scan to obtain BMDThe result is that onlyof Americans who are at risk of suffe ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government